Steris plc stock (IE00BFY8C754): Ownership shift as Swedish fund cuts NYSE stake

Steris plc shares on the NYSE drew attention on 06/01/2026 after a Swedish pension fund disclosed that it had significantly reduced its position, adding a fresh ownership angle to the US-listed medical technology group ahead of further analyst assessments.

Steris plc shares remained in focus on the New York Stock Exchange on 06/01/2026 after a recent regulatory filing showed that Swedish pension investor Första AP-fonden had pared back its position in the US-listed medical technology group, highlighting an updated institutional ownership picture for the stock according to MarketBeat as of 06/01/2026.

The filing, summarized by MarketBeat on 06/01/2026, indicated that Första AP-fonden reduced its stake in Steris by 23.7% during the fourth quarter of 2025, trimming its holding to 29,900 shares of the NYSE-listed company. The position was valued at about USD 7.8 million at the time of the filing, underscoring that Steris continues to feature in the portfolios of large Nordic institutions despite the partial exit.

On its primary home exchange in the United States, Steris trades on the NYSE under the ticker STE, with the shares closing at USD 212.52 on 05/29/2026, according to MarketBeat as of 05/29/2026. Extended-hours data from the same source showed the stock changing hands at USD 211.50 after the regular session on 05/29/2026, reflecting modest after-hours activity ahead of the new trading week.

For German-based investors, Steris is also available on secondary trading venues such as Tradegate and Frankfurt, where the stock is typically quoted in euro during European trading hours, providing an alternative route to gain exposure to the NYSE listing via local brokers.

The updated ownership disclosure from Första AP-fonden adds a fresh data point to Steris’s shareholder structure, coming on top of the company’s role as a mid-to-large-cap healthcare name in the US market and a component of institutional portfolios that seek defensive exposure to hospital-focused equipment and sterilization services.

The stock traded at 212.52 USD on 05/29/2026 on the New York Stock Exchange, according to MarketBeat as of 05/29/2026, framing the valuation backdrop against which the Swedish fund adjusted its position.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Steris plc
• Sector/industry: Medical equipment and infection prevention solutions
• Headquarters/country: Dublin, Ireland
• Core markets: United States, Europe and other international healthcare markets
• Key revenue drivers: Sterilization equipment, infection prevention products and outsourced sterilization services for hospitals, pharmaceutical manufacturers and life science customers
• Home exchange/listing venue: New York Stock Exchange (STE)
• Trading currency: USD

Steris plc: core business model

Steris focuses on providing hospitals, pharmaceutical producers and research facilities with sterilization equipment, infection control consumables and related service offerings that generate recurring revenue from installed systems and contract sterilization capacity.

What banks and research houses say about Steris plc

Analyst coverage of Steris on Wall Street remains active, with data compiled by MarketBeat showing that, as of 05/29/2026, four research analysts covering the NYSE-listed stock assigned an overall "Moderate Buy" consensus rating. According to the same MarketBeat overview, the average 12-month price target across these analysts stood at USD 278.00, with individual targets ranging from USD 269.00 on the low end to USD 295.00 on the high end as of 05/29/2026.

The MarketBeat data imply that the consensus price objective of USD 278.00 would represent upside potential of about 30.81% from the closing price of USD 212.52 on 05/29/2026, although the actual performance will depend on future operating results and broader healthcare-sector sentiment. The presence of a "Moderate Buy" label from the analyst set underscores that, as of late May 2026, external research views Steris positively in the context of the US medical technology universe, even as individual institutional investors like Första AP-fonden fine-tune their exposure.

Conclusion

The latest ownership disclosure showing that Sweden’s Första AP-fonden cut its Steris stake by nearly a quarter in the fourth quarter of 2025 adds a new angle to the institutional backdrop for the NYSE-listed healthcare equipment group. In parallel, a "Moderate Buy" analyst consensus and an average 12-month price target of USD 278.00 as of 05/29/2026 frame how research houses position the stock in the wider medical technology sector. How Steris trades around these inputs will likely depend on the company’s upcoming operating updates, movements in the broader US healthcare space and any further changes in large shareholders’ positions.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.